User's guide to JAK inhibitors in inflammatory bowel disease
Inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD), are remitting and relapsing disorders of the gastrointestinal tract, highlighted by the dysregulation of pro- and anti-inflammatory mediators, which lead to mucosal damage. These conditions cause a signi...
Main Authors: | Ted A. Spiewak, DO, Anish Patel, DO |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Current Research in Pharmacology and Drug Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257122000165 |
Similar Items
-
Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib
by: Carolina Neudorfer, MD, et al.
Published: (2023-09-01) -
Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment
by: Hiroshi Nakase
Published: (2023-07-01) -
Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore
by: Scott D. Lee, et al.
Published: (2023-02-01) -
The positive effect of JAK inhibitor tofacitinib in the treatment of primary Sjögren’s syndrome: a clinical case
by: D.G. Rekalov, et al.
Published: (2023-03-01) -
The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
by: Diqin Yan, et al.
Published: (2022-08-01)